STOCK TITAN

Armistice Capital reports 2.5M AVNS shares (5.39%) in Schedule 13G

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Armistice Capital, LLC and Steven Boyd filed a Schedule 13G reporting beneficial ownership of 2,500,000 shares of Avanos Medical, Inc. (AVNS) common stock, representing 5.39% of the class. They report shared voting and shared dispositive power over these shares, with no sole voting or dispositive power. The filing cites 46,418,907 shares outstanding as of October 29, 2025 (per the issuer’s 10‑Q).

The filing is certified as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control. The date of the event requiring the filing is September 30, 2025.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:11/14/2025
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:11/14/2025
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: November 14, 2025 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What stake did Armistice Capital report in AVNS?

Armistice Capital reported beneficial ownership of 2,500,000 AVNS shares, equal to 5.39% of the class.

What is the basis for the 5.39% calculation for AVNS?

The percentage is based on 46,418,907 shares outstanding as of October 29, 2025, as disclosed in the issuer’s 10‑Q.

Does Armistice Capital have sole or shared voting power in AVNS?

They report 0 sole voting power and 2,500,000 shares with shared voting power.

What type of filing did Armistice Capital and Steven Boyd submit for AVNS?

A Schedule 13G, indicating a passive ownership position.

When was the event date triggering this 13G for AVNS?

The date of event requiring the filing is September 30, 2025.

Did the filers state any intent to influence control at AVNS?

No. They certified the shares were acquired and held in the ordinary course and not to influence control.

Who signed the AVNS Schedule 13G on behalf of the filers?

It was signed by Steven Boyd, Managing Member of Armistice Capital, LLC.
Avanos Medical

NYSE:AVNS

AVNS Rankings

AVNS Latest News

AVNS Latest SEC Filings

AVNS Stock Data

521.28M
44.52M
4.07%
98.38%
5.89%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
ALPHARETTA